Relx to See Accelerated Midterm Division Growth Amid 'Rapid' Adoption of AI Platform, BofA Says

12:58 AM EST, 11/05/2026 (MT Newswires) -- BofA Global Research believes the quick adoption of Relx's (REL.L, REN.AS) new artificial intelligence-powered platform, LeapSpace, will help accelerate midterm revenue growth for its scientific, technical and medical division. "LeapSpace making rapid progress, reinforcing our confidence it can positively impact divisional growth mid-term- now serving c.1,000 institutions or c.8-10% just c.10 months post-launch. Given 12month budget cycles we see scope for further/large step-up into 2027. It now covers c.25m articles (from 15m+ at launch) or 56% share of citations, showing the prerequisite of broad content access potentially being met. Early from a revenue standpoint but the opportunity is potentially significant - RELX interfaces with 10m+ researchers," analysts said Wednesday after the British information analytics company hosted a seminar for the scientific, technical and medical unit. The research firm said Relx's scientific, technical and medical business, which generates 30% of group revenue, is "one of the most consequential" medium-term drivers with an "improved" quality of growth. BofA noted that this momentum is supported by broad-based expansion across both primary research and databases and tools. As such, analysts reiterated the stocks' buy ratings and price objectives of 40 pounds sterling and 46.50 euros. BofA also included the British information analytics company in its "25 for 2026" list.